Welcome back to the Psychedelic Invest week in review. Here are the stories that moved the psychedelic sector during the week of June 22–28, 2026 — from clinical readouts to regulatory shifts and the capital flowing through the space.
Definium Therapeutics, Inc. (formerly MindMed) (DFTX): Definium's Phase 3 Emerge study of DT120 (LSD) meets primary endpoint in major depression
Definium Therapeutics, the rebranded MindMed, reported positive topline results from its pivotal Phase 3 Emerge study of DT120 (formerly MM120, an LSD orally disintegrating tablet) in major depressive disorder. A single 100 microgram dose delivered an 8.1-point placebo-adjusted MADRS improvement at Week 6 (p<0.0001) and a 7.3-point advantage at Week 12, with no serious adverse events or suicidality signal. The readout is the first positive randomized Phase 3 result for a single-dose lysergide compound in a major psychiatric indication, materially de-risking the company's lead program.
Source: businesswire.com
Definium Therapeutics, Inc. (formerly MindMed) (DFTX): Definium prices upsized $700 million public offering after Phase 3 win
One day after its positive Emerge readout, Definium priced an upsized underwritten offering of 20,588,236 shares at $34.00 each for roughly $700 million in gross proceeds, up from an initially proposed $500 million. Underwriters received an option for an additional 3,088,235 shares. Proceeds are earmarked for R&D, commercialization preparation for DT120 ODT if approved, and general corporate purposes, substantially bolstering the balance sheet ahead of a potential regulatory filing.
Source: businesswire.com
Cybin Inc. (d/b/a Helus Pharma) (HELP): Helus Pharma reports APPROACH Phase 3 enrollment past 86% and launches $50M offering
Cybin, now operating as Helus Pharma, said enrollment in its APPROACH Phase 3 trial of HLP003, a Breakthrough Therapy-designated deuterated psilocin analog for adjunctive major depressive disorder, had surpassed 86%, keeping topline data on track for Q4 2026. Alongside the update the company announced a US$50 million underwritten offering to fund the program and a second Phase 3 study, EMBRACE. The progress and financing advance one of the sector's most closely watched late-stage psilocybin-based programs.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.